Skip to main content

Akebia Therapeutics, Inc.

AKBA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001517022

No open-market purchases or sales by Akebia Therapeutics, Inc. insiders were filed in the last 90 days; 170 institutions reported holding it in 13F filings for Q2 2026, worth $123.2M in total; no superinvestor holds it.

Superinvestors holding AKBA, Q2 2026

See all superinvestors

No superinvestor reported holding AKBA in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of AKBA each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q4 2021

    0 superinvestors holding at quarter end

    Sold out
    Maverick Capital
  2. Q3 2021

    1 superinvestor holding at quarter end

    New
    Maverick Capital
  3. Q2 2021

    0 superinvestors holding at quarter end

    Sold out
    Maverick Capital